Results 61 to 70 of about 5,184 (154)

Nirmatrelvir and ritonavir combination against COVID‐19 caused by omicron BA.2.2 in the elderly: A single‐center large observational study

Immunity, Inflammation and Disease
Background Since coronavirus 2019 (COVID‐19) swept the world, a variety of novel therapeutic and prevention strategies have been developed, among which nirmatrelvir–ritonavir is highly recommended.
Can Chen, Ranyi Li, Shuliang Xing, Lei Cao, Yue Qu, Qianzhou Lv, Xiaoyu Li, Zhangzhang Chen   +7 more
doaj   +1 more source

Cardiovascular Drug Interactions with Nirmatrelvir/Ritonavir for COVID-19: Considerations for Daily Practice

European Cardiology Review
Cardiovascular disease is associated with progression to severe COVID-19 and patients with the condition are among those in whom early antiviral therapy should be warranted.
Andrea Di Lenarda, Nicola Ferri, Massimiliano Lanzafame, Eva Agostina Montuori, Luciano Pacelli   +4 more
doaj   +1 more source

Patterns of use of oral antivirals for COVID-19 in people 70 years and over in Victoria, Australia: a linked data study

BMC Infectious Diseases
Background Two oral antivirals for treatment of COVID-19 are available in Australia, nirmatrelvir-ritonavir, which is recommended, and molnupiravir, which is approved for use when nirmatrelvir-ritonavir is contraindicated.
Laura J. Edwards, Anish Scaria, Allen C. Cheng, Janaki Amin, Elizabeth J. Robinson, Caroline Sumpton, Bette Liu   +6 more
doaj   +1 more source

Clinical real-world effectiveness of nirmatrelvir/ritonavir for the treatment of SARS-CoV-2 infection: A meta-analysis

Tungs’ Medical Journal
Background: According to the Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients (EPIC-HR) study, compared with a placebo, nirmatrelvir/ritonavir significantly reduced the risk of coronavirus disease 2019 (COVID-19)-related ...
Chienhsiu Huang, Sufang Kuo, Lichen Lin
doaj   +1 more source

An Intersectional Analysis of Social Deprivation and Patient Characteristics on Nirmatrelvir-Ritonavir for Treatment of COVID-19 in U.S. Primary Care Practices, 2021 to 2023

Journal of Primary Care & Community Health
Objective: Calculate rates of nirmatrelvir-ritonavir prescription and assess area-level social deprivation as an effect modifier of patient characteristics on nirmatrelvir-ritonavir for the treatment of COVID-19.
Esther E. Velásquez, Neil S. Kamdar, Nathaniel Hendrix, Xiaoyu Wang, Robert L. Phillips, David H. Rehkopf   +5 more
doaj   +1 more source

Abstracts From AIDS 2026, the 26th International AIDS Conference, 26 – 31 July 2026 Rio de Janeiro, Brazil & virtual

Journal of the International AIDS Society, Volume 29, Issue S4, July 2026.
wiley   +1 more source

Clinical Outcome and 7-Day Virological Clearance in High-Risk Patients with Mild–Moderate COVID-19 Treated with Molnupiravir, Nirmatrelvir/Ritonavir, or Remdesivir

Infectious Diseases and Therapy
Introduction We compared the effectiveness and virological clearance (VC) at day 7 (T7) post-treatment with molnupiravir, nirmatrelvir/ritonavir, and remdesivir in SARS-CoV-2-infected patients at high risk (HR) for clinical progression.
Francesca Bai, Tomaso Beringheli, Virginia Vitaletti, Andrea Santoro, Francesco Molà, Alessandro Copes, Nicole Gemignani, Sofia Pettenuzzo, Roberto Castoldi, Benedetta Varisco, Riccardo Nardo, Lorenzo Brando Lundgren, Riccardo Ligresti, Matteo Sala, Lorenzo Albertini, Matteo Augello, Lorenzo Biasioli, Valeria Bono, Roberta Rovito, Teresa Bini, Sabrina Passarella, Nicola Vincenzo Orfeo, Antonella d’Arminio Monforte, Giulia Marchetti   +23 more
doaj   +1 more source

Incidence of COVID-19 Symptom Rebound After Treatment with Remdesivir

Infectious Disease Reports
Background/Objectives: Recent in vitro data suggest that remdesivir might be less likely than nirmatrelvir–ritonavir to be associated with COVID-19 rebound. We compared the incidence of symptom rebound in our remdesivir-treated cohort with rates reported
Kalpana Gupta, William J. O’Brien, Judith Strymish, Anna Chen, Katherine Linsenmeyer, Rebecca Madjarov, Michael E. Charness   +6 more
doaj   +1 more source

Nirmatrelvir/ritonavir treatment and the risk of post-COVID condition over 180 days in Malaysia

BMC Infectious Diseases
Background The effect of nirmatrelvir/ritonavir on preventing post-COVID condition (PCC) in the BA4, BA5, and XBB Omicron predominant periods is not well understood.
Ee Vien Low, Mohan Dass Pathmanathan, Yi Yang Ten, Suresh Kumar Chidambaram, Wee Ric Kim, Wei Jia Lee, Zhi Wei Teh, Maheshwara Rao Appannan, Mastura Ismail, Azah Abdul Samad, Kalaiarasu M. Peariasamy   +10 more
doaj   +1 more source

Nirmatrelvir/ritonavir treatment of patients with COVID-19 taking tacrolimus: case series describing the results of drug–drug interactions

Journal of International Medical Research
Nirmatrelvir/ritonavir is a novel drug combination that is authorized by the Food and Drug Administration for the treatment of coronavirus disease 2019 (COVID-19).
Dan Shen, Yinhua Gong, Yulan Qian, Jianguo Zhu, Jie Gao   +4 more
doaj   +1 more source